

 #CARDIOTOX [CARDIOTOX.ES](https://www.cardiotox.es)

CARDIOTOX 26

12-13 NOVEMBER

MADRID



VENUE

Meeting Place Castellana 81, Madrid

Thursday, 12th November

08:30 – 09:00 **Welcome and registration**

09:00 – 09:05 **Inauguration**

Teresa López-Fernández, Cardiologist, Madrid

Raúl Córdoba, Hematologist, Madrid

Isabel Rodríguez, Radiation oncologist, Madrid

Álvaro Pinto, Medical oncologist, Madrid

09:05 – 09:35 **TRANSLATING CARDIO-ONCOLOGY ADVANCES INTO CLINICAL CARE**

Chairs:

Javier de Castro, Medical oncologist, Madrid

Raúl Córdoba, Hematologist, Madrid

Isabel Rodríguez, Radiation oncologist, Madrid

09:05 – 09:15 Cardio-oncology 2026: key advances for the clinic

Teresa López-Fernández, Cardiologist, Madrid

09:15 – 09:25 Proton therapy: is the heart still at risk?

Marianne Aznar, Radiation Oncology Physics, Manchester

09:25 – 09:35 Discussion

09:35 – 10:30 **FROM BENCH TO BEDSIDE**

Immune cancer therapies and the mechanisms underlying cardiac immune-related adverse events

Chairs:

Carlo Gabriele Tocchetti, Cardiologist, Naples

Virginia Calvo, Medical oncologist, Madrid

09:35 – 09:45 Mechanisms of ICI-related myotoxicity

Pilar Martín, Biologist, Madrid

09:45 – 09:55 ICI myotoxicity: from mechanisms to targeted treatment

Joe-Elie Salem, Cardiologist, Paris

09:55 – 10:05 Translational biomarkers in immune-related cardiotoxicity: from inflammatory cells to risk stratification

María Rosaria Galdiero, Clinical immunologist, Naples

10:05 – 10:15 T cell-based cancer therapies and associated cardiac irAEs

Lorenz Lehmann, Cardiologist, Heidelberg

10:15 – 10:30 Discussion

10:30 – 11:00

Coffee break

11:00 – 11:45

MEET THE EXPERTS

Lung cancer therapies: cardiovascular risk, rechallenge and practical surveillance

Chairs:

Virginia Calvo, Medical oncologist, Madrid

Pedro Moliner, Cardiologist, Barcelona

11:00 – 11:10

ICI rechallenge after myotoxicity: time for reassessment?

Joe-Elie Salem, Cardiologist, Paris

11:10 – 11:20

EGFR-targeted therapies: cardiovascular toxicity and monitoring

Oliver Higuera, Medical oncologist, Madrid

11:20 – 11:30

ALK inhibitors: practical surveillance and metabolic management

Dolores Isla, Medical oncologist, Zaragoza

11:30 – 11:45

Discussion

11:45 – 12:15

IN FOCUS

Tyrosine kinase inhibitors in CML: balancing vascular risk and efficacy

Chairs:

Valentín García, Hematologist, Madrid

Marta Fanlo Maresma, Internal Medicine, Barcelona

Panel discussion:

Santiago Osorio, Hematologist, Madrid

Pilar Agudo, Cardiologist, Madrid

Juan Pedro Justel, General practitioner, Madrid

12:15 – 13:15

CARDIAC IMAGING IN CARDIO-ONCOLOGY

From findings to decisions

Chairs:

Victoria Delgado, Cardiologist, Barcelona

Pilar Zamora, Medical oncologist, Madrid

12:15 – 12:25

How imaging in cardio-oncology has changed over the last decade

Dolores Mesa, Cardiologist, Córdoba

12:25 – 12:35

GLS drop: treat or observe?

Belén Terol, Cardiologist, Madrid

12:35 – 12:45

CMR: When does it alter therapy?

Rocío Eiros, Cardiologist, Salamanca

12:45 – 12:55

CMR in suspected ICI-myocarditis: diagnostic thresholds and pitfalls

Chiara Bucciarelli-Ducci, Cardiologist, London

12:55 – 13:05

Asymptomatic ASCVD in cancer survivorship: what next?

Inés García Lunar, Cardiologist, Madrid

13:05 – 13:20

Discussion

13:20 – 15:20

Lunch break: Tutorials / Satellite Symposium

15:20 – 16:15

FROM BENCH TO BEDSIDE

The vicious cycle of cancer therapy-induced cardiac injury: mechanisms and treatment windows

Chairs:

Lorenz Lehmann, Cardiologist, Heidelberg

Inés García Lunar, Cardiologist, Madrid

15:20 – 15:30

Anthracycline cardiotoxicity: molecular mechanisms that inform prevention

Alessandra Ghigo, Cardiologist, Torino

15:30 – 15:40

Exercise in CTRCD: mechanistic rationale and treatment windows

Carlo Gabriele Tocchetti, Cardiologist, Naples

15:40 – 15:50

Neurohormonal inhibition in CTRCD: preclinical and clinical evidence

Pietro Ameri, Cardiologist, Genoa

15:50 – 16:00

Reversible vs irreversible CTRCD: biological continuum or distinct entities?

Dimitrios Farmakis, Cardiologist, Athens

16:00 – 16:15

Discussion

CARDIOTOX 26

12-13 NOVEMBER
MADRID

VENUE Meeting Place Castellana 81, Madrid

16:15 – 17:00 **CARDIAC IMAGING IN CARDIO-ONCOLOGY**
Smarter imaging workflows for patient-centred care

17:00 – 18:00 **CLINICAL CASE FORUM**
Acute cardio-oncology: are we ready for the 24-hour challenge?

Chairs:

Eduardo Zatarain, Cardiologist, Madrid

Pietro Ameri, Cardiologist, Genoa

Antonia Sambola, Cardiologist, Barcelona

17:00 – 17:15 ICI-myotoxicity: early signals and grey zones

Jorge Álvarez Troncoso, Internal Medicine, Madrid

17:15 – 17:30 Acute coronary syndrome during cancer treatment

Pedro Moliner, Cardiologist, Barcelona

17:30 – 17:45 Cardiovascular complications of CRS in CAR-T therapy

Annamaria Brioli, Hematologist, Hannover

17:45 – 18:00 Acute pulmonary embolism in cancer: when to escalate

Sandra Rosillo, Cardiologist, Madrid

18:00 – 19:00 **TUTORIALS / SATELLITE SYMPOSIUM**

Friday, 13th November

08:30 – 09:10

SYMPOSIUM

Cardiovascular risk across cancer therapies and survivorship

Chairs:

Peter van der Meer, Cardiologist, Groningen

Cristina Mitroi, Cardiologist, Madrid

08:30 – 08:40

Cardiovascular risk with immunotherapy-based combinations

Diego Jiménez Bou, Medical oncologist, Madrid

08:40 – 08:50

Endocrine and targeted therapies in breast cancer: the unresolved long-term cardiovascular burden

Jutta Bergler-Klein, Cardiologist, Vienna

08:50 – 09:00

Biomarkers for risk stratification and long-term surveillance

Daniela Cardinale, Cardiologist, Milan

09:00 – 09:10

Discussion

09:10 – 09:50

IN FOCUS

Cardiac amyloidosis in the cardio-oncology clinic: recognition and targeted therapies

Chairs:

Chiara Bucciarelli-Ducci, Cardiologist, London

Dimitrios Farmakis, Cardiologist, Athens

09:10 – 09:20

Clinical and imaging red flags

Rocío Eiros, Cardiologist, Salamanca

09:20 – 09:30

ATTR cardiac amyloidosis: recent therapeutic advances

Peter van der Meer, Cardiologist, Groningen

09:30 – 09:40

AL cardiac amyloidosis: emerging treatment strategies and cardiac outcomes

Annamaria Brioli, Hematologist, Hannover

09:40 – 09:50

Discussion

-
- 09:50 – 10:30** **GRACE DIGITAL MONITORING ACADEMY**
Remote monitoring in cardio-oncology: ready for implementation or still a work in progress?
Chairs:
TBD
- 09:50 – 09:55** Introduction
TBD
- 09:55 – 10:05** Remote monitoring during cancer care: workload reducer or complexity amplifier?
TBD
- 10:05 – 10:15** Remote monitoring during cancer care: who really needs it?
TBD
- 10:15 – 10:30** Discussion

10:30 – 11:00 **Coffee break**

-
- 11:00 – 12:00** **CLINICAL CASE FORUM**
Vascular, valvular and metabolic challenges in patients with cancer
Chairs:
Pilar Zamora, Medical oncologist, Madrid
Victoria Delgado, Cardiologist, Barcelona
Antonia Sambola, Cardiologist, Barcelona
- 11:00 – 11:15** Fluoropyrimidine-associated chest pain: acute management and next steps
Cristina Contreras, Cardiologist, Madrid
- 11:15 – 11:30** Severe aortic stenosis in active cancer: timing TAVI and competing clinical priorities
Amparo Martínez Monzonis, Cardiologist, Santiago de Compostela
- 11:30 – 11:45** When anticoagulation leads to bleeding: what to do and when to act?
Cristina Pascual, Hematologist, Madrid
- 11:45 – 12:00** Obesity in cancer care: ignore or treat from day one?
Almudena Castro, Cardiologist, Madrid

-
- 12:00 – 12:50** **FROM BENCH TO BEDSIDE**
Genetic and acquired determinants of cardiotoxicity: from predisposition to second hits
Chairs:
Cristina Mitroi, Cardiologist, Madrid
Álvaro Pinto, Medical oncologist, Madrid
- 12:00 – 12:10** CHIP as a cardiovascular risk modifier: what matters in cardio-oncology?
José Javier Fuster, Biochemist, Madrid
- 12:10 – 12:20** CHIP in lymphoma: biological links and implications for cardiac injury
Miguel Canales, Hematologist, Pamplona
- 12:20 – 12:30** TTN truncating variants before anthracycline therapy: proceed, modify or protect?
Juan Caro, Cardiologist, Madrid
- 12:30 – 12:40** Cardiomyopathy variants and cardiotoxicity: second hit or misdiagnosis
Rebeca Lorca, Cardiologist, Oviedo
- 12:40 – 12:50** Discussion
-
- 12:50 – 13:30** **MEET THE EXPERTS**
Anticipating and managing cardiovascular risk in patients with prostate and renal cancer
Chairs:
Álvaro Pinto, Medical oncologist, Madrid
Sergio Cinza, General practitioner, Santiago de Compostela
- 12:50 – 13:00** Cardiovascular adverse events with tyrosine-kinase inhibitors for renal cancer
Guillermo de Velasco, Medical oncologist, Madrid
- 13:00 – 13:10** Hormone therapy for prostate cancer and cardiovascular toxicity
Natalia Vidal, Medical oncologist, Madrid
- 13:10 – 13:20** Pre-treatment assessments in patients with prostate cancer
Estefanía Linares, Urologist, Madrid
- 13:20 – 13:30** Discussion

13:30 – 14:15

IN FOCUS

BTK inhibitors in CLL: new strategies, new cardiovascular questions

Chairs:

Raúl Córdoba, Hematologist, Madrid

Rebeca Lorca, Cardiologist, Oviedo

13:30 – 13:40

Real-world evidence: beyond clinical trials

Alicia Aguirre, Hematologist, Córdoba

13:40 – 13:50

Finite vs continuous treatment: cardiovascular risk after treatment discontinuation

Lucrecia Yáñez, Hematologist, Santander

13:50 – 14:00

Non-covalent BTK inhibitors: a new drug class with a favourable cardiovascular safety profile

José Ángel Hernández Rivas, Hematologist, Madrid

14:00 – 14:15

Discussion

14:15 – 16:00

Lunch break: Tutorials / Satellite Symposium

16:00 – 17:00

CLINICAL CASE FORUM

Prevention and permissive cardiotoxicity: are we doing too much or too little?

Chairs:

Vicente Pallarés, General practitioner, Castellón

Ana Martín, Cardiologist, Salamanca

16:00 – 16:15

Albuminuria during VEGF inhibition: marker or mandate to act

Pilar Mazón, Cardiologist, Santiago de Compostela

16:15 – 16:30

Permissive cardiotoxicity: LVEF-led or context-led decision-making?

Eduardo Zatarain, Cardiologist, Madrid

16:30 – 16:45

Myocardial injury in acute leukaemia: a triple-hit of host, disease, and treatment

Gabriela Rodríguez Macías, Hematologist, Madrid

16:45 – 17:00

CV surveillance after HSCT: defining who is truly high-risk

Irene Sánchez Vadillo, Hematologist, Madrid

CARDIOTOX 26

12-13 NOVEMBER
MADRID

VENUE Meeting Place Castellana 81, Madrid

17:00 – 17:45	SYMPOSIUM Building the roadmap for the next generation of cardio-oncology care Chairs: Raúl Córdoba , Hematologist, Madrid Teresa López-Fernández , Cardiologist, Madrid
17:00 – 17:15	Translational research priorities in cardio-oncology Borja Ibáñez , Cardiologist, Madrid
17:15 – 17:30	Cardio-oncology roadmap: from trials and real-world data to future guidelines Alexander Lyon , Cardiologist, London
17:30 – 17:45	Discussion

17:45 – 17:55	CLOSING REMARKS
----------------------	------------------------

CARDIOTOX 26

12-13 NOVEMBER
MADRID



Secretaría técnica

 **tactics**

 Barcelona · Madrid

 93 451 17 24

 info@tacticsmd.net

 www.tacticsmd.net